First, the combo patent application can be broadened later after strategic narrowing for what indication it is being tested in. It also is very likely to add csf1r, which is highly likely to be the ultimate combination and is possibly, imo, in the patent system as a new application filing, but not published for proprietary reasons.
Second, Dr. Pazdur is a fan of combining trial phases in order to speed development. What Ex isn’t telling you is that Ex also believes the DC, CI, CSF1R combo is a massive break through in science, and the current two part patent app and trial are headed to testing all three in the spore trial. My expectation is the trial will be ridiculously effective and concluded very early. They’ve know about that three part combo potential for at least six years.
Third, the assignment of the current combo patent app to three parties was almost certainly accompanied by a contract spelling out future rights. Ex pretends like this is a big deal, it’s almost certainly a non-issue.
Fourth, Major pharma are retooling their CIs to go from an infusion administration to a subcutaneous administration. The real benefit of this will be the ability to sequence and overlap with combination therapies.
Fifth, NWBO already has recently patented improved DCVax-Direct, and applied for patenting the next level of DC therapy in hyperactive dendritic cells.
It is no sure thing that one or more BP will get their patents for changing CI administration from infusion to subcutaneous.
News 
Market Data 
Discover 
